These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

62 related items for PubMed ID: 3081842

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dose requirement for replacement therapy in hemophilia A.
    Allain JP.
    Thromb Haemost; 1979 Oct 31; 42(3):825-31. PubMed ID: 505399
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR, Tuller J, Johnson JA.
    Haemophilia; 1999 Mar 31; 5(2):88-95. PubMed ID: 10215955
    [Abstract] [Full Text] [Related]

  • 7. Thawed cryoprecipitate stored for 6 h at room temperature: a potential alternative to factor VIII concentrate for continuous infusion.
    Pesquera-Lepatan LM, Hernandez FG, Lim RD, Chua MN.
    Haemophilia; 2004 Nov 31; 10(6):684-8. PubMed ID: 15569162
    [Abstract] [Full Text] [Related]

  • 8. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J, Berntorp E, Lindvall K, Björkman S.
    Haemophilia; 2004 Nov 31; 10(6):689-97. PubMed ID: 15569163
    [Abstract] [Full Text] [Related]

  • 9. In vitro factor VIII recovery during the delivery of ultrapure factor VIII concentrate by continuous infusion.
    DiMichele DM, Lasak ME, Miller CH.
    Am J Hematol; 1996 Feb 31; 51(2):99-103. PubMed ID: 8579073
    [Abstract] [Full Text] [Related]

  • 10. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S, Folkesson A, Berntorp E.
    Haemophilia; 2007 Jan 31; 13(1):2-8. PubMed ID: 17212717
    [Abstract] [Full Text] [Related]

  • 11. In vivo recovery of factor VIII: a comparison of one-stage and two-stage assay methods.
    Nilsson IM, Kirkwood TB, Barrowcliffe TW.
    Thromb Haemost; 1979 Dec 21; 42(4):1230-9. PubMed ID: 120619
    [Abstract] [Full Text] [Related]

  • 12. Lyophilized cryoprecipitate for children with hemophilia A.
    Nuchprayoon I, Sahasittiwat S, Kittikalayawong A, Chantanakajornfung A.
    J Med Assoc Thai; 2002 Jun 21; 85 Suppl 1():S293-7. PubMed ID: 12188426
    [Abstract] [Full Text] [Related]

  • 13. Peripheral blood hematocrit in critically ill surgical patients: an imprecise surrogate of true red blood cell volume.
    Takanishi DM, Yu M, Lurie F, Biuk-Aghai E, Yamauchi H, Ho HC, Chapital AD.
    Anesth Analg; 2008 Jun 21; 106(6):1808-12. PubMed ID: 18499614
    [Abstract] [Full Text] [Related]

  • 14. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A, Dannhauser D, Pontara E, Bertomoro A, Orazi B, Santarossa L, Zerbinati P, Girolami A.
    Blood Coagul Fibrinolysis; 1996 Jul 21; 7(5):549-53. PubMed ID: 8874865
    [Abstract] [Full Text] [Related]

  • 15. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma.
    Caudill JS, Nichols WL, Plumhoff EA, Schulte SL, Winters JL, Gastineau DA, Rodriguez V.
    Transfusion; 2009 Apr 21; 49(4):765-70. PubMed ID: 19192257
    [Abstract] [Full Text] [Related]

  • 16. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R.
    Ther Drug Monit; 2007 Feb 21; 29(1):20-6. PubMed ID: 17304146
    [Abstract] [Full Text] [Related]

  • 17. [Home treatment in hemophilia].
    Pabinger I, Niessner H, Korninger C, Nowotny C, Stain M, Kyrle PA, Lechner K.
    Wien Klin Wochenschr; 1987 Nov 20; 99(22):773-7. PubMed ID: 3124354
    [Abstract] [Full Text] [Related]

  • 18. Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII).
    Garcia VV, Silva IA, Borrasca AL.
    Thromb Haemost; 1982 Aug 24; 48(1):91-3. PubMed ID: 6813999
    [Abstract] [Full Text] [Related]

  • 19. Clinical application of a chromogenic substrate method for determination of factor VIII activity.
    Rosén S, Andersson M, Blombäck M, Hägglund U, Larrieu MJ, Wolf M, Boyer C, Rothschild C, Nilsson IM, Sjörin E.
    Thromb Haemost; 1985 Dec 17; 54(4):818-23. PubMed ID: 3937277
    [Abstract] [Full Text] [Related]

  • 20. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K, Berntorp E, ten Cate JW, Johnsson H, Peters M, Savidge G, Tengborn L, Spira J, Stahl C.
    Thromb Haemost; 1997 Feb 17; 77(2):298-302. PubMed ID: 9157585
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.